Core Viewpoint - Huaxi Biological asserts that claims exempt from scientific verification are inherently pseudoscientific, emphasizing the necessity of measurable and verifiable scientific methods in the industry [1][2]. Group 1: Huaxi Biological's Position - Huaxi Biological argues that the absence of standardized testing methods does not negate the existence of scientific methods for validation, using their product "Runbaiyan" as an example of verifiable testing results for recombinant collagen [2][5]. - The company highlights the use of High-Performance Liquid Chromatography-High-Resolution Mass Spectrometry (HPLC-HRMS) as a reliable method to accurately measure recombinant collagen content, claiming it effectively avoids complex matrix interference [5][12]. Group 2: Response from Juzhi Biological - Juzhi Biological acknowledged the limitations of their existing quality standards and testing methods in a statement, indicating a need for continuous optimization to meet industry advancements [6][9]. - The company plans to collaborate with research institutions to enhance the qualitative and quantitative detection methods for recombinant collagen in cosmetics, aiming for greater transparency and industry standardization [9][10]. Group 3: Testing Method Controversy - The debate over testing methods arose when beauty blogger Dazui Doctor (Hao Yu) questioned the recombinant collagen content in a product, using a high-precision HPLC amino acid quantification method, which Juzhi Biological claimed was not included in industry standards [10][11]. - Experts noted that both HPLC amino acid quantification and HPLC-HRMS methods have their unique applications and challenges, particularly in detecting low concentrations of collagen in complex cosmetic formulations [12][13].

以下文章来源于金融八卦女频道 ，作者乌彦祖假正经 金融八卦女频道 . 有深度、有温度、有态度，在这里读懂财富。 鹬蚌相争有人得利。 作者：乌彦祖假正经 来源：金融八卦女频道 医美圈都不用"暗箭"了，直接"明枪"。 网红"大嘴博士"指责港股上市公司巨子生物"疑似造假"的舆论战，正式升级为两家医美巨头 的"大乱斗"。 6月1日晚19:30分，华熙生物发布文章《关于支持郝宇博士维护消费者权益的声明》，称跟郝 宇（"大嘴博士"）有商业合作，支持他、保护他。同时喊话："汝求战，便得战!" 3个小时后，巨子生物开始"应战"：5月30日收到"大嘴博士"（郝宇）所用检测机构的道歉声 明，严令禁止大嘴博士使用这个《检测报告》。 到底什么仇，什么怨，让两家上市公司唇枪舌战？ 2021年以来，华熙生物看家法宝"玻尿酸"在资本市场上被冷落，销量和股价都在下降，而巨 子生物的"重组胶原蛋白"却风生水起，一直涨不停。按照双方声明透露的信息，这期间，私下 没少"互射冷箭"。 网红"打假"上市公司， 竟扯出两位"医美女王"的多年暗战？ 华熙生物跟巨子生物的争端早有"预兆"。 5月17日都快深夜12点了，昔日"医美茅"华熙生物突然发布了一篇言 ...

以下文章来源于金融八卦女频道 ，作者乌彦祖假正经 金融八卦女频道 . 有深度、有温度、有态度，在这里读懂财富。 鹬蚌相争有人得利。 作者：乌彦祖假正经 来源：金融八卦女频道 医美圈都不用"暗箭"了，直接"明枪"。 网红"大嘴博士"指责港股上市公司巨子生物"疑似造假"的舆论战，正式升级为两家医美巨头 的"大乱斗"。 6月1日晚19:30分，华熙生物发布文章《关于支持郝宇博士维护消费者权益的声明》，称跟郝 宇（"大嘴博士"）有商业合作，支持他、保护他。同时喊话："汝求战，便得战!" 3个小时后，巨子生物开始"应战"：5月30日收到"大嘴博士"（郝宇）所用检测机构的道歉声 明，严令禁止大嘴博士使用这个《检测报告》。 到底什么仇，什么怨，让两家上市公司唇枪舌战？ 2021年以来，华熙生物看家法宝"玻尿酸"在资本市场上被冷落，销量和股价都在下降，而巨 子生物的"重组胶原蛋白"却风生水起，一直涨不停。按照双方声明透露的信息，这期间，私下 没少"互射冷箭"。 文字都是在指责券商，但细品一下就会发觉似乎"意有所指"，华熙生物列举的券商研报里，很 多文章都在点名夸赞"巨子生物"。华熙生物董事长，有"玻尿酸女王"之称的赵燕，也曾 ...

Core Viewpoint - The controversy surrounding the collagen content in the product "Human-Like Recombinant Collagen" from the brand Kefu Mei, owned by the company Giant Bio, has raised significant concerns regarding product integrity and testing methods [1][2][3]. Group 1: Controversy Details - KOL "Dr. Big Mouth" (Hao Yu) claimed that tests showed the collagen content in Kefu Mei's product was only 0.0177% using HPLC amino acid quantification [1]. - Giant Bio responded by stating their tests indicated collagen content greater than 0.1%, contradicting the claims made by Hao Yu, but third-party test results are still pending [2]. - Hao Yu further questioned Giant Bio's testing methods, suggesting that the use of the biuret method could lead to inflated results due to the presence of sodium polyglutamate in the product [3]. Group 2: Previous Issues and Impact - This is not the first controversy for Kefu Mei in 2023, as the brand was previously accused of illegally adding epidermal growth factor (EGF), which led to a public trust crisis [4][5]. - The Shaanxi Provincial Drug Administration investigated the previous claims and found no violations after sampling [6]. - The outcome of the current controversy is crucial for Giant Bio's future performance, as Kefu Mei is projected to generate revenue of 4.542 billion yuan in 2024, contributing over 80% to the company's total revenue [6]. Group 3: Market Reaction - Despite the unresolved testing results, the controversy has significantly impacted Giant Bio's stock price [7]. - As of May 29, Giant Bio's market capitalization was 72.9 billion HKD, having lost 12.8 billion HKD since early May [8].

作 者丨凌晨 编 辑丨骆一帆 最新的进展是，该博主在5月27日晚，公开了一份自称为"巨子生物向各大平台的举报材料"。 近日，一条"巨子生物疑似造假：重组胶原竟然测不到胶原！"的视频及图文网帖，引爆讨 论。 其中，检测方法对于成分含量影响的争议，双方各执一词。 可复美送检方法被公开？ 21世纪经济报道记者查阅多篇知网文献发现，双缩脲法在蛋白质检测中仍有争议。 2008年《河北化工》刊文《蛋白质含量测定方法的比较》中提到，双缩脲法中样品的取用量 对测定结果的准确性有显著影响。双缩脲法可快速测定蛋白质含量，试剂单一，方法简便， 但灵敏度差，测定范围为 1～20 mg 蛋白质。适用于需要快速,但并不需要十分精确的蛋白质 测定。 2019年，来自广东医科大学药学院、广东省医疗器械质量监督检验所的六位行业人士撰文中 提到："缩脲法测定Ⅰ型胶原蛋白含量，测定方法经济，简便，测定结果准确，重现性 好。"其中，Ⅰ型胶原蛋白是皮肤的主要成分，广泛应用于皮肤修复和化妆品行业。 据显示，上述材料名为"关于申请协调删除恶意诋毁诽谤内容的函"。 其中提到巨子生物采用《中华人民共和国药典》2020版四部通则0731第三法及中华人民共和 国 ...

近期，巨子生物（02367.HK）旗下的可复美重组胶原蛋白精华"涉嫌严重造假"事件在网上持续发酵， 提出质疑的"大嘴博士"郝宇也成为了这场舆论的核心人物。 在这场"造假门"中，检测方式成为各方关注的核心。可复美在声明中驳斥称："大嘴博士"的不实指控 中，使用的检测方法并未列入行业标准，因该检测方法以及相对应的样品预处理方法未经严格的方法学 验证，检测结果不准确。截至目前，对方尚未向我们索要该重组胶原蛋白原料，我们也尚未对外提供或 出售该原料，对方是无法进行其所采用检测方法的方法学验证的。因此，其检测结果不可信。 对此，郝宇5月26日接受南都湾财社记者采访时回应称：我们用的高精度HPLC氨基酸定量法，该方法 在国际上应用非常广泛，这也是国际通行的标准方法，该方法被反复验证过，比如测量氨基酸的含量 时，HPLC方法的准确性、特异性都非常好。所以，只要是氨基酸构成的肽蛋白质，还是氨基酸单体， 都能精准地定量测出来。 对于检测方式等问题，南都湾财社记者联系巨子生物并发函，截至发稿暂未获得回应。此前，可复美在 《声明》中表示：已经委托多家权威第三方检测机构相关产品采用多种检测方法进一步进行检测，检测 需要时间，拿到最新 ...

Core Viewpoint - The ongoing dispute regarding the detection methods for recombinant collagen in cosmetics has raised significant concerns about the reliability of testing methods used by the company, Juzhi Biotechnology, and the implications for consumer trust [1][4]. Group 1: Detection Methods - Juzhi Biotechnology referenced the "Detection Methods for Recombinant Collagen Content" from the Chinese medical industry standard YY/T 1947-2025, which includes two main types of detection methods [1][2]. - The first method is the "mass spectrometry method," which is primarily used for tissue regeneration materials and is not suitable for complex cosmetic formulations due to potential interference from other ingredients [2][3]. - The second method includes six techniques, with the Kjeldahl method being the most likely choice for Juzhi Biotechnology, despite its limitations in accurately assessing specific proteins in complex formulations [2][3]. Group 2: Product Withdrawal and Consumer Trust - Juzhi Biotechnology's product, Human-Like Recombinant Collagen Essence, has been removed from major sales channels, raising questions about the company's testing results [4]. - The claim that testing for recombinant collagen content requires raw materials from Juzhi is misleading, as the product itself can be purchased for independent testing [4][5]. - The company's practice of not selling raw materials externally may pose risks, as it limits independent verification and peer review of their recombinant collagen [4][5]. Group 3: Questions and Concerns - There are significant concerns regarding the independence of any future sample testing if Juzhi Biotechnology provides the samples themselves, as this could lead to questions about the integrity of the results [5]. - Two critical questions remain unanswered by Juzhi Biotechnology: the absence of the core amino acid glycine in the tests and the potential misrepresentation of dipeptides as "mini collagen" [5].